Partex.AI Enters AI-Driven Collaboration with Bayer to Unlock Potential New Indications and Accelerate Global Out-Licensing Opportunities

Frankfurt, Germany – Partex.AI, a global innovator in AI-powered pharmaceutical

development, today announced the successful completion of a pilot collaboration with Bayer

aimed at selecting and prioritizing potential new indications for two clinical stage Bayer assets

using Partex’s proprietary AI technology.

Building on Partex’s proven expertise in AI-driven life cycle management, the pilot collaboration

leveraged the Ontosight™ Knowledge Graph and Ontosight Asset42™ platform to

systematically evaluate biological relevance, clinical probability of success, and commercial

potential across a wide spectrum of therapeutic opportunities.

As part of the pilot, Partex delivered a robust evidence package, detailing the prioritized new

indications supported by AI-generated biological evidence and rationale, clinical feasibility

assessment, and commercial potential. This expanded data offering may enhance the lifecycle potential of the assets and reveal new potential strategic pathways for clinical development.

“By combining Bayer’s deep scientific understanding with Partex’s AI-powered Ontosight platform, we have been able to suggest new possibilities for two promising assets,” said Dr. Gunjan Bhardwaj, Founder & CEO, Partex.AI. “Our proprietary AI platform demonstrates how advanced analytics and knowledge graph-driven insights can reshape lifecycle management and accelerate value creation.”

The enriched data would allow Bayer to effectively identify and engage future partners for the

new indications with a stronger evidence base and clearer visibility into indication attractiveness.

This pilot marks another milestone in Partex’s mission to transform drug development using

data-driven intelligence, and it demonstrates how global pharma leaders can leverage AI to

optimize asset potential, accelerate partnerships, and broaden therapeutic impact.

About Partex.AI

Partex.AI – The world’s largest AI-powered therapeutic asset accelerator. Our vision is

to address inefficiencies in drug discovery & development using AI at scale, bringing

discovered drug candidates faster to right patients efficiently.

Our services accelerate the data-scrutinizing process, empowering pharma and biotech

companies to speed up their progress in drug discovery and development.

What we do:

Therapeutics: Identification of late-stage preclinical and early clinical assets with strong

science but limited development paths. AI models refine and advance these therapies

toward key value milestones. Currently incubating three oncology assets through

dedicated SPVs.

Drug Asset Exchange: AI-enabled platform for pharma and biotech to evaluate,

reposition, and transact deprioritized or off-strategy assets. Supports efficient pipeline

optimization through flexible, data-backed collaboration models.

Labs: Integration of advanced functional assays with high-throughput screening to

validate AI predictions. A closed-loop framework that combines computational

modeling with experimental biology to deliver robust, disease-relevant evidence.

Real-World Data: Global partnerships with healthcare providers to unlock Real-World

Data for drug development and treatment optimization. Enabling data-driven insights

that support better outcomes and smarter clinical decision-making.